Real-world comparative outcomes of first-line immune combinations (ICI-ICI vs ICI-TKI) in metastatic renal cell carcinoma with sarcomatoid features

Introduction

Although first-line immune-based combinations have reshaped the management of metastatic renal cell carcinoma (mRCC), relevant unmet clinical needs remain. Sarcomatoid feature is a negative prognostic factor that confers sensitivity to immunotherapy, yet the optimal ICI combination in this subgroup is still unclear.